The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) was developed to assess clinically relevant cognitive and physical symptoms associated with depression that are not adequately assessed by traditional measures. Although the CPFQ has been shown previously to be a reliable and valid measure, the purpose of the present study was to provide additional evidence using larger samples from 4 independent clinical trials that were designed to test the efficacy and safety of different antidepressants.
Methods
The psychometric analyses were based on data from 4 independent clinical trials that were designed to test the safety and efficacy of different antidepressants. Reliability of the items and of the overall questionnaire was evaluated with principal components analysis, whereas validity was assessed by associations of the questionnaire scores with convergent and divergent external criteria.
Results
Overall, the results have replicated previous findings that the CPFQ has good internal reliability. Validation also is strengthened by the demonstration of predictive differences among known groups as well as a sensitivity to change with antidepressant treatment.
Conclusions
Results support the use of the CPFQ as a valuable instrument for the detection of clinically relevant symptoms that are not captured by typical measures of depression used for the assessment of treatment outcomes.
Get full access to this article
View all access options for this article.
References
1.
FavaM, MischoulonD, IosifescuD, . A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom.2012;81;87–97.
2.
EdwardsJG, AndersonI.Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs.1999;57:507–533.
3.
HamiltonM.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
4.
MontgomerySA, ÅsbergM.A new depression scale designed to be sensitive to change. Br J Psychiatry.1979;134:382–389.
5.
Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
6.
CassanoP, FavaM.Depression and public health: an overview. J Psychosom Res. 2002;53:849–857.
7.
FavaM, BallS, NelsonJC, . Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety. 2014;31:250–257.
8.
JuddLL, PaulusMJ, SchettlerPJ, . Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?Am J Psychiatry. 2000;157:1501–1504.
9.
MillerIW, KeitnerGI, SchatzbergAF, . The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59:608–619.
10.
FavaM, GravesLM, BenazziF, . A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67;1754–1759.
11.
FavaM, IosifescuDV, PedrelliP, . Reliability and validity of the Massachusetts General Hospital cognitive and physical functioning questionnaire. Psychother Psychosom. 2009;78:91–97.
12.
FavaM, AsnisGM, ShrivastavaR, . Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:222–230.
13.
LevkovitzY, AlpertJE, BrintzCE, . Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012;136:1174–1178.
14.
JohnsMW.A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.1991;14:540–545.
15.
MendozaTR, WangXS, CleelandCS, . The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer.1999;85:1186–1196.
16.
MarinRS, BiedrzyckiRC, FirinciogullariS.Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143–162.
PangalloB, DellvaMA, D'SouzaDN, . A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res. 2011;45:748–755.
19.
WilliamsJB, KobakKA, BechP, . The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23: 120–129.
20.
RushAJ, TrivediMH, IbrahimHM, . The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDSC) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.
21.
SheehanDV. Sheehan Disability Scale. In: RushAJJr, FirstMB, BlackerD, eds. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association; 2000:113–115.
22.
BallS, DellvaMA, D'SouzaDN, . A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord. 2014;167:215–223.
23.
MatzaLS, PhillipsGA, RevickiDA, . Development and validation of a patient-report measure of fatigue associated with depression. J Affect Disord. 2011;134:294–303.
24.
RaskinJ, GeorgeT, GrangerRE, . Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. Psychiatr Res.2012;46:667–674.
25.
OakesTM, MyersAL, MarangellLB, . Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol. 2012;27:47–56.
26.
BagbyRM, RyderAG, SchullerDR, . The Hamilton Depression Rating Scale: has the gold standard become a lead weight?Am J Psychiatry.2004;161:2163–2177.
27.
SpitzerRL, KroenkeK, WilliamsJB.Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737–1744.
28.
LöweB, UnützerJ, CallahanCM, . Monitoring depression treatment outcomes with the Patient Health Questionnaire–9. Med Care. 2004;42:1194–1201.
29.
ShimizuY, KitagawaN, MitsuiN, . Neurocognitive impairments and quality of life in unemployed patients with remitted major depressive disorder. Psychiatry Res. 2013;210:913–918.
30.
McIntyreRS, LophavenS, OlsenCK.A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults [published online April 30, 2014]. Int J Neuropsychopharmacol. doi: http://dx.doi.org/10.1017/S1461145714000546.
31.
MadhooM, KeefeRS, RothRM, . Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39:1388–1398.
32.
BocktingCL, SpinhovenP, KoeterMW, ; Depression Evaluation Longitudinal Therapy Assessment Study Group. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J Clin Psychiatry.2006;67:747–755.
33.
PaykelES, RamanaR, CooperZ, . Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171–1180.
34.
RomeraI, MontejoAL, CaballeroF, . Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study. BMC Psychiatry. 2011;11:69.
35.
McIntyreR.Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry.2013:74(suppl 2):14–18.
36.
DalyEJ, TrivediMH, FavaM, . The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the Suicide Assessment Methodology Study. J Clin Psychopharmacol. 2011;31:31–38.
